About Us
Avalyn is a clinical-stage biotech company developing inhaled therapies to treat rare respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases.
Our goal is to deliver inhaled formulations of effective medicines directly to lung tissue, thus potentially enhancing efficacy and avoiding side effects associated with systemic drug delivery.
Our Pipeline
Our programs are championed by a leadership team with unparalleled expertise in the development of inhaled drugs. Avalyn’s pipeline includes two clinical stage programs, AP01 (inhaled pirfenidone) and AP02 (inhaled nintedanib), and a preclinical stage program, AP03 (a fixed dose combination of inhaled pirfenidone and nintedanib).
Latest News
May 21, 2026
Avalyn Announces Additional Long-term Data on AP01, Inhaled Pirfenidone, for the Treatment of Pulmonary Fibrosis to be Presented at the European Alliance of Associations for Rheumatology 2026
Read MoreMay 5, 2026
Avalyn to Present Patient-Centered Research on AP01 Delivery and Supportive Care Experiences at American Thoracic Society 2026 International Conference
Read MoreMay 1, 2026
Avalyn Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
Read MoreBiotechTV Featuring Avalyn's CEO
Avalyn’s CEO, Lyn Baranowski, describes the Company’s treatment approach for pulmonary fibrosis, where there is a large unmet need despite the three oral therapies available commercially. She explains how Avalyn’s nebulization method is designed to improve the substantial tolerability issues associated with current treatment options by directly targeting the lung through inhalation.